Skip to content

Ligand Pharmaceuticals LGND Ohtuvayre inventors — Financial Royalty Assets, Net

Other product segments

Qarziba
$103.24M

Similar metrics at other companies

Revolution Medicines, Inc. logo
RVMDIntangibles (Net)
$55.8M-1.1%
IonQ logo
IONQIntangibles (Net)
$781.09M+2,668%
Zoetis logo
ZTSIntangibles (Net)
$745M-14.9%
Natera, Inc. logo
NTRAIntangibles (Net)
$367.36M
Zimmer Biomet Holdings logo
ZBHIntangibles (Net)
$4.55B+1.8%
PayPal Holdings, Inc. logo
PYPLIntangible assets — net
$206M-30.4%

Other financials

Income statement

See full
Revenue$51.7M+14.1%
Operating income$17.4M+148%
Net income-$13.3M+68.6%
EPS (diluted)-$0.67+69.7%

Balance sheet

See full
Cash & equivalents$115.1M+140%
Total debt$5.1M+14.2%
Total equity$997.3M+25.4%
Total assets$1.5B+69.2%

Cash flow

See full
Operating cash flow$48.7M+291%
CapEx$228.0K+6.5%
Free cash flow$48.5M+289%

Valuation

See full
Market cap$5.51B+96.7%
Enterprise value$5.4B+95.4%
P/E35.9×
P/S20.1×+4.6×

Profitability

See full
Gross margin91.9%
Operating margin34.5%+23.0pp
Net margin55.9%+35.7pp
FCF margin44.8%+16.8pp

Returns & leverage

See full
Return on equity17.1%+11.5pp
Debt / equity0.0×
Current ratio21.3×+16.0×

Where this comes from

Reported directly by Ligand Pharmaceuticals in its filing.

Tagged under the XBRL concept lgnd:FinancialRoyaltyAssetsNet.

The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ligand Pharmaceuticals's ohtuvayre inventors — financial royalty assets, net.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Ligand Pharmaceuticals's ohtuvayre inventors — financial royalty assets, net?
Ligand Pharmaceuticals (LGND) reported ohtuvayre inventors — financial royalty assets, net of $17.84M in Q1 2026.
What does ohtuvayre inventors — financial royalty assets, net mean?
This metric represents the net book value of royalty assets associated with the Ohtuvayre product line after accounting for accumulated amortization and valuation allowances. It serves as a measure of the current carrying value of the asset on the balance sheet, representing the expected future economic benefits. Investors track this to evaluate the remaining value of the company's intellectual property and its potential for future cash generation.